ORIGINAL ARTICLE

Cost Analysis of Sentinel Lymph Node Biopsy in Melanoma

T. Martínez-Menchón,a,* P. Sánchez-Pedreño,a J. Martínez-Escribano,a R. Corbalán-Vélez,a E. Martínez-Barba b

a Servicio de Dermatología, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
b Servicio de Anatomía Patológica, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

Received 15 April 2014; accepted 18 October 2014
Available online 24 February 2015

KEYWORDS
Melanoma;
Sentinel lymph node biopsy

Abstract
Introduction and objective: Sentinel lymph node biopsy (SLNB) is the most useful tool for node staging in melanoma. SLNB facilitates selective dissection of lymph nodes, that is, the performance of lymphadenectomy only in patients with sentinel nodes positive for metastasis. Our aim was to assess the cost of SLNB, given that this procedure has become the standard of care for patients with melanoma and must be performed whenever patients are to be enrolled in clinical trials. Furthermore, the literature on the economic impact of SLNB in Spain is scarce.
Method: From 2007 to 2010, we prospectively collected data for 100 patients undergoing SLNB followed by transhilar bivalving and multiple-level sectioning of the node for histology. Our estimation of the cost of the technique was based on official pricing and fee schedules for the Spanish region of Murcia.
Results: The rate of node-positive cases in our series was 20%, and the mean number of nodes biopsied was 1.96; 44% of the patients in the series had thin melanomas. The total cost was estimated at between €9486.57 and €10 471.29. Histopathology accounted for a considerable portion of the cost (€5769.36).
Discussion: The cost of SLNB is high, consistent with amounts described for a US setting. Optimal use of SLNB will come with the increasingly appropriate selection of patients who should undergo the procedure and the standardization of a protocol for histopathologic evaluation that is both sensitive and easy to perform.
© 2014 Elsevier España, S.L.U. and AEDV. All rights reserved.

* Please cite this article as: Martínez-Menchón T, Sánchez-Pedreño P, Martínez-Escribano J, Corbalán-Vélez R, Martínez-Barba E. Evaluación del coste económico de la técnica de la biopsia selectiva del ganglio centinela en melanoma. Actas Dermosifiliogr. 2015;106:201–207.
* Corresponding author. Tel.: +657742724.
E-mail address: teresammenchon@gmail.com (T. Martínez-Menchón).

1578-2190/© 2014 Elsevier España, S.L.U. and AEDV. All rights reserved.
Introduction

The optimal node staging approach in melanoma is based on sentinel lymph node biopsy (SLNB), which serves as a guide for selective lymphadenectomy performed in node-positive cases. Guidelines for referring patients for SLNB are constantly changing. In general, biopsy is recommended in cases of primary melanoma without evidence of regional or distant metastasis when the risk of node metastasis is at least 10%, which is to say clinical stages IB and IIA, B, and C according to the 7th edition of the staging manual of the American Joint Committee on Cancer. Selection criteria have not yet been standardized for cases with a Breslow thickness of less than 0.75 mm, but defining a treatment approach for this subgroup of patients will become crucial given that they now account for 60% to 70% of melanomas diagnosed in large hospitals. This group has grown more rapidly than others in recent years.

A lower threshold for significant node metastasis has not yet been established; thus, a finding of a single isolated melanoma cell in the sentinel node would be sufficient grounds for a positive classification and, therefore, would lead to a change in therapeutic approach. Given that the most recent melanoma guidelines of the American Joint Committee on Cancer stipulate that identifying a single melanoma cell should be the goal, histologic processing of the biopsied material should be as exhaustive as possible. As processing is inevitably incomplete, however, finding single cells will be largely a matter of chance.

Clear standardization of an approach to histologic processing of the sentinel node is also lacking, though transhilar bivalving and examination of parallel slices (breadloafing) (Fig. 1) are techniques that have received attention.

Our principal aim was to assess the cost of SLNB in our practice setting, a referral hospital for the Spanish region of Murcia, given that this procedure has become the standard of care for patients with melanoma and is also necessary whenever patients are to be enrolled in clinical trials. Few cost studies have been done in Spain, however, and our view is that the economic impact of SLNB has been underestimated. A prospective observational study was therefore designed to estimate SLNB-related costs in our hospital.

Material and Methods

Information for 100 patients undergoing SLNB in the period from 2007 to 2010 was recorded in a database. A standardized transhilar bivalving technique was used in all cases. The inclusion criteria were as follows: primary cutaneous melanoma with a Breslow thickness of at least 1 mm or 0.75 mm if there were concurrent signs associated with greater likelihood of node positivity (i.e., ulceration, regression, age under 40 years, or lymph vessel invasion). Melanomas in pediatric patients were excluded because the natural history of these tumors differs in adults and children.

The study was carried out in the dermatology department of Hospital Clínico Universitario Virgen de la Arrixaca, which is the referral hospital for SLNB. The hospital’s catchment area has approximately 560,000 inhabitants.
Cost Analysis of Sentinel Lymph Node Biopsy in Melanoma

SLNB Technique

We injected a technetium-99 radiolabeled tracer (Lymphoscint, Amersham, Saluggia, Italy) with colloid particles 50 to 100 nm in diameter. The amount of solution was 1 mL, distributed in 4 intradermal injections of 250 μCi, each containing 1 μCi (37 MBq) of the tracer. The injections were made around the lesion (or around the scar in the case of previously excised lesions closed by direct suture without flaps or graft reconstructions). A tracer uptake time of 2 to 4 hours was allowed before the procedure. After the gamma-camera guided injections, sequential and dynamic images were recorded every 10 seconds for 5 minutes. Immediately afterwards, a static image of a single projection was recorded for 180 seconds (matrix, 256 x 256 pixels). We considered the gamma camera to be correctly placed if 1 or more draining nodes could be identified; the first such nodes that appeared were considered sentinel nodes and their locations were marked. If nodes were not found, another acquisition was attempted an hour later; yet another attempt 2 hours later might also be made. If a sentinel or other draining node was adequately located it was biopsied in the operating room, with the aid of images from the preoperative lymphoscintigram and guidance from a handheld gamma probe. To minimize damage to the node, the biopsy was harvested with Babcock forceps, and diathermy for hemostasis was used cautiously.

Histologic Processing

The processing protocol included transeptile bivalving of the node and multiple-level parallel sectioning. The sentinel nodes were fixed in formalin for 24 hours and then embedded in paraffin. Five serial sections of 5 μm each were stained with hematoxylin and eosin (H&E) (2 slices) for histology; immunohistostaining with antibodies for S100, HMB-45, and Melan-A completed the processing of these zero-level studies. Then, 250 μ was sliced into 5 additional sections for histologic and immunohistochimical staining of another level. This process of step-sectioning the material was repeated at intervals of 250 μ. Each was approximately 4 mm in diameter so on average, 9 levels could be studied once the bivalved node had been placed in cassettes for paraffin embedding. As described above, the sections sliced from each level were processed with H&E, anti-Melan-A, anti-S100, and anti-HMB-45 staining to give an average of 45 processed sections for the pathologist to evaluate in total (in levels corresponding to 0, 250, 500, 750, 1000, 1250, 1500, 1750, and 2000 μ) (Fig. 2).

Fee and Price Schedule

Our cost study was based on unit prices found in the fee and price schedule published in the regional government’s official gazette (Boletín Oficial de la Región de Murcia, February 2013). Our hospital’s accounting and analysis department did not make available their data on actual spending. The published prices are used by the hospital to invoice third parties and are approximate indications of real costs. Both direct and indirect costs were included, such that staffing and maintenance of the facilities were reflected. There is no unit price specified for whole the set of services related to SLNB in the diagnosis of melanoma; we therefore added up the costs for each of the component procedures performed in the process.

Results

Of a total of 100 patients diagnosed with melanoma who underwent SLNB from 2007 to 2010, all inclusion criteria were met by 99 patients, whose data entered the analysis.
The mean Breslow thickness was 2.02 mm (median, 1 mm); 20% of the cases were node-positive. A mean (SD) of 1.96 (1.46) nodes (95% CI, 0.50–3.42 nodes) were excised per patient (median, 1); for cost estimates, the mean was rounded up to 2. Table 1 shows descriptive data for the series. The Breslow thickness was less than 1 mm in 44 (44%) patients; 1 of these patients (2.2% of the 44) had a positive node.

The hospital’s fees for the various procedures required for SLNB are shown in Table 2.

Accordingly, the total cost of biopsying an axillary node was €3717.21; the cost was €4701.93 for an inguinal node. If more than 1 drainage pathway was identified, costs increased.

Histopathologic processing of multiple-level sections amounted to approximately €2884.68 in this hospital series (Table 3). Given that our hospital biopsied 2 nodes per case on average, the price of histopathologic processing came to €5769.36 per case. The total cost of SLNB therefore ranged from €9486.57 to €10 471.29.

**Table 1** Main Characteristics of the Patient Series.

<table>
<thead>
<tr>
<th>Variables</th>
<th>2007–2010 Series</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean Breslow thickness, mm</strong></td>
<td>2.02</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>41 (41.41%)</td>
</tr>
<tr>
<td>Women</td>
<td>58 (58.58%)</td>
</tr>
<tr>
<td><strong>Location</strong></td>
<td></td>
</tr>
<tr>
<td>Limbs</td>
<td>42 (42.85%)</td>
</tr>
<tr>
<td>Trunk</td>
<td>49 (50%)</td>
</tr>
<tr>
<td>Head and neck</td>
<td>7 (7.15%)</td>
</tr>
<tr>
<td><strong>Findings of histopathology</strong></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>79 (79.79%)</td>
</tr>
<tr>
<td>Positive</td>
<td>20 (20.20%)</td>
</tr>
<tr>
<td>Isolated cells</td>
<td>4 (4.04%)</td>
</tr>
<tr>
<td>Micrometastasis</td>
<td>3 (3.03%)</td>
</tr>
<tr>
<td>Macrometastasis</td>
<td>13 (13.13%)</td>
</tr>
<tr>
<td><strong>No. of nodes excised</strong></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>51 (51.51%)</td>
</tr>
<tr>
<td>2</td>
<td>28 (28.28%)</td>
</tr>
<tr>
<td>≥ 3</td>
<td>20 (20.20%)</td>
</tr>
</tbody>
</table>

**Table 2** General Costs Necessary for SLNB, Excluding Histopathologic Processing Costs.

<table>
<thead>
<tr>
<th>Item</th>
<th>Cost, €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conventional hospitalization per day; price code, A.1.3</td>
<td>583.60</td>
</tr>
<tr>
<td>Radical excision of skin lesion (with safety margins), ICD-9-CM.86.40</td>
<td>1726.28</td>
</tr>
<tr>
<td>Skin graft or flap, ICD-9-CM.86.60</td>
<td>1726.28</td>
</tr>
<tr>
<td>Nuclear medicine study, sentinel node in melanoma; price code, A.5.1.N.8</td>
<td>200.38</td>
</tr>
<tr>
<td>Axillary lymph node excision, ICD-9-CM.40.23</td>
<td>1206.95</td>
</tr>
<tr>
<td>Inguinal lymph node excision, ICD-9-CM.40.24</td>
<td>2191.67</td>
</tr>
</tbody>
</table>

Abbreviations: ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; SLNB, sentinel lymph node biopsy.

**Table 3** Costs Related to the Histopathologic Processing of Sentinel Lymph Nodes.

<table>
<thead>
<tr>
<th>Stain</th>
<th>No.</th>
<th>Unit Price, €</th>
<th>Total Price, €</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;E</td>
<td>9</td>
<td>65.13</td>
<td>586.17</td>
</tr>
<tr>
<td>Anti-Melan A</td>
<td>9</td>
<td>85.13</td>
<td>766.17</td>
</tr>
<tr>
<td>Anti-S100</td>
<td>9</td>
<td>85.13</td>
<td>766.17</td>
</tr>
<tr>
<td>Anti-HMB-45</td>
<td>9</td>
<td>85.13</td>
<td>766.17</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>2884.68</td>
</tr>
</tbody>
</table>

Discussion

This study found that SLNB-related costs ranged between €9486.57 and €10 471.29 in this prospectively enrolled series of 99 patients treated in our referral hospital in the Spanish region of Murcia.

As a basis for comparison with other procedures performed in the hospital, we mention that the unit prices for kidney and liver transplants are €279 327.71 and €92 581.04, respectively, indicating that the cost of SLNB is by no means negligible.

Our hospital has been performing SLNB for approximately 20 years. The multidisciplinary team responsible for the procedure is comprised of members of the dermatology, general surgery, nuclear medicine, and pathology departments. An
operating room for major outpatient surgery is used, and patients are usually hospitalized for 1 day. As no immediate postoperative complications that prolonged hospitalization developed in this series, all patients were discharged the next day.

The costs we calculated are consistent with the range of $10,000 to $15,000 (€7620 to €11,431) reported earlier by a US hospital.7

Only one other study in Spain has analyzed the costs of the various steps in the diagnosis and treatment of cutaneous melanoma.8 The authors of that study estimated the general costs of SLNB to be €682.24 (with 1 day of hospitalization and re-excision of the melanoma scar with margins of 2 cm), but they did not describe the process they used for sentinel-node histology.

A cost-effectiveness study in Australia by Morton et al.9 estimated that their procedure (without study of safety margins) cost €1902.45. We point out that the approach to histologic processing was not detailed in that study either, even though this component of SLNB is responsible for higher costs.

Our results show that histologic processing accounts for a large portion of the cost of SLNB. Many processing approaches have been used, and their ability to detect positive nodes depends on how exhaustively the material is assessed. Examination of parallel slices (breadloafing) must be distinguished from transhilar bivalving approaches (Table 4). The European Organisation for Research and Treatment of Cancer currently recommends that the sentinel node be examined with the histopathologic method described by Cook et al.5 This approach relies on transhilar bivalving and assessment of material in step sections of 50 μ. At each step, or processing level, 4 slices are cut and prepared with H&E, anti-S100, anti-HMB-45, and Pan Melanoma Plus stains. Some material is left unstained in case the node must be reassessed. This protocol examines about 700 to 800 μ, not the entire node. In fact, the recommended method is neither rapid nor easy to standardize, and it generates costs that many hospitals are unable to absorb. Findings from a study by Bastistatou et al.,10 based on a telephone survey of dermatopathologists who were members of the European Society of Pathology, illustrated these problems: only 48% of the respondents used transhilar bivalving and only 42% used a method of parallel slicing. The respondents examined from 1 to 20 steps. The most complete processing approach involves multiple slices for histology and the use of immunohistochemical stains that add considerably to the overall expense. Our current approach to assessing the sentinel node follows the guidelines for treating melanoma in the

| Author1 | Processing Technique | Multiple-Level Sectioning | No. of Sections | Staining | %  
|---------|----------------------|---------------------------|----------------|----------|---
| Spanknebel (routine pathology) | Transhilar bivalving | 1 level | 1 frozen, 1 paraffin-embedded | H&E | 20  
| Spanknebel (extended pathology) | Transhilar bivalving | 20 levels, every 50 μ | 60 | H&E, anti-S100, anti-HMB-45 | 61  
| Cook (protocol 1) | Transhilar bivalving | Not done | 8 | H&E, anti-S100, anti-HMB-45 | 18  
| Cook (protocol 2) | Transhilar bivalving | 2 levels, every 50 μ | 12 | H&E, anti-S100, anti-HMB-45 | 25  
| Cook (protocol 3) | Transhilar bivalving | 5 levels, every 50 μ | 20 | H&E, anti-S100, anti-HMB-45, Pan Melanoma Plus | 34  
| Abrahamsen | Transhilar bivalving | Every 250 μ (entire node) | According to size of node | H&E, anti-S100, anti-HMB-45, anti-Melan-A | 28  
| Bostick, Takeuchi | Transhilar bivalving | 80 μ, frozen + 3 levels every 40 μ | 4–16 | H&E, anti-S100, anti-HMB-45 | 24  
| Starz | Parallel to the longitudinal axis | 1 mm, with scalpel | According to size of node | H&E, anti-S100, anti-HMB-45 | 38  
| Li | Parallel to the shortest diameter | 1 level | 4 | H&E, anti-S100, anti-HMB-45 | 15  
| Rimoldi | Parallel to the shortest diameter | 2–3 mm, with scalpel | 12–20 | H&E, anti-S100, anti-HMB-45, anti-tyrosinase, anti-Melan-A | 24  

Abbreviation: H&E, hematoxylin and eosin.
1 Adapted from Mangas et al.6
2 When authors describe more than one process, the technique is named in parentheses.
3 Percentage of positive nodes found.

Table 4 Summary of Approaches to Assessment of the Sentinel Node

| Author1 | Processing Technique | Multiple-Level Sectioning | No. of Sections | Staining | %  
|---------|----------------------|---------------------------|----------------|----------|---
| Spanknebel (routine pathology) | Transhilar bivalving | 1 level | 1 frozen, 1 paraffin-embedded | H&E | 20  
| Spanknebel (extended pathology) | Transhilar bivalving | 20 levels, every 50 μ | 60 | H&E, anti-S100, anti-HMB-45 | 61  
| Cook (protocol 1) | Transhilar bivalving | Not done | 8 | H&E, anti-S100, anti-HMB-45 | 18  
| Cook (protocol 2) | Transhilar bivalving | 2 levels, every 50 μ | 12 | H&E, anti-S100, anti-HMB-45 | 25  
| Cook (protocol 3) | Transhilar bivalving | 5 levels, every 50 μ | 20 | H&E, anti-S100, anti-HMB-45, Pan Melanoma Plus | 34  
| Abrahamsen | Transhilar bivalving | Every 250 μ (entire node) | According to size of node | H&E, anti-S100, anti-HMB-45, anti-Melan-A | 28  
| Bostick, Takeuchi | Transhilar bivalving | 80 μ, frozen + 3 levels every 40 μ | 4–16 | H&E, anti-S100, anti-HMB-45 | 24  
| Starz | Parallel to the longitudinal axis | 1 mm, with scalpel | According to size of node | H&E, anti-S100, anti-HMB-45 | 38  
| Li | Parallel to the shortest diameter | 1 level | 4 | H&E, anti-S100, anti-HMB-45 | 15  
| Rimoldi | Parallel to the shortest diameter | 2–3 mm, with scalpel | 12–20 | H&E, anti-S100, anti-HMB-45, anti-tyrosinase, anti-Melan-A | 24  

Abbreviation: H&E, hematoxylin and eosin.
1 Adapted from Mangas et al.6
2 When authors describe more than one process, the technique is named in parentheses.
3 Percentage of positive nodes found.
region of Murcia; very similar guidelines are used in Valencia.

How long the pathologist takes to assess all the slices should also be taken into consideration. We estimated assessment took 2 minutes per slice on average; thus if 36 to 45 are to be assessed, a pathologist will spend at least 72 minutes on a single node. As a case involves 2 nodes on average, 144 minutes of a pathologist’s time will be required for each patient undergoing SLNB.

The use of this technique should be as restricted as possible. In a case with a low Breslow index, SLNB may be justified when the likelihood of node positivity is at least 10%, but the procedure is currently being ordered by clinicians even when risk of positivity is lower. Furthermore, the overall survival rates for patients with thin melanomas are excellent, ranging from 85% to 99%, and patients with melanomas less than 1 mm thick are becoming the largest group (accounting for 60% to 70% of new diagnoses in large hospitals). Forty-four percent of our patients who underwent SLNB had tumors with a Breslow thickness of less than 1 mm, and in that group only 1 patient (2.2%) had a positive node.

Thus, 43 node-negative SLNBs and 1 node-positive SLNB were performed in this subgroup. Given that SLNB ranges in cost from €9486.57 to €10471.29, the cost of detecting a single positive node in the group of patients with melanomas less than 1 mm thick was between €417409.08 and €460736.76 in our series. Patients were enrolled in this study over a 3-year period, suggesting an incidence of 0.33 node-positive cases per year. Thus, the estimated annual cost would have been €137744.97 to €152043.13.

If pathologic assessment were extended only to the melanoma excision scar, the cost would have been €1791.41; multiplied by 44 patients the total would be €78822.04.

Therefore, SLNB leads to a total cost increase of €338587.04 to €381914.72; per patient, the increase attributable to SLNB would be €7695.16 to €8679.88.

Agnese et al. calculated a loss of 17.1 years of life per melanoma. Dividing the increased cost generated by SLNB by the loss of potentially lost years of life suggests an estimated cost of €19800.40 to €22334.19 for each year of life saved. The literature suggests a figure of approximately $35000 (about €27000) as the upper limit considered reasonable to spend on SLNB per life saved. This purely economic indicator is very difficult to evaluate, but in theory the amounts we calculated suggest that our costs fall within the recommended limits.

Our method for calculating the cost per year of life saved was based on the approach of Agnese et al., who estimated the cost to be €43156.26 in a series of 99 melanomas with a Breslow thickness less than 1 mm. This figure was higher than in our study, and the authors had to assess 91 cases to find a single positive node. They concluded that SLNB does not appear to be cost-effective and that it should be questioned in cases of thin melanomas.

Our cost-effectiveness data suggest that the selection of patients for SLNB should be improved, especially in thin tumors (Breslow thickness less than 1 mm), given that the procedure is costly and, in our practice setting, the diagnostic yield is low in this subgroup of patients. These concerns are important at this time because new approaches to treatment for metastatic melanoma could be useful adjuncts to therapy in the near future. It is therefore crucial to be able to identify melanomas that have reached the node, so that such new treatments could be offered if necessary.

Optimal use of SLNB should be based on improving patient selection and standardizing the histopathologic processing protocol to establish one that is sensitive but also simple. Optimization is a dynamic process and is being intensely debated at this time. Studies in larger cohorts will be required so that conclusions can be based on more data.

This study analyzed the costs of SLNB in our hospital. Even though further analyses are needed, our calculations give some indication of what is being spent. Our data can serve to raise awareness of economic issues related to the use of SLNB in terms carrying out the procedure.

Ethical Disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this investigation.

Data confidentiality. The authors declare that no private patient data are disclosed in this article.

Right to privacy and informed consent. The authors declare that no private patient data are disclosed in this article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References


8. Almazán-Fernández FM, Serrano-Ortega S, Moreno-Villalonga JJ. Descriptive study of the costs of diagnosis and treatment


